Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Unknown1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07343453Phase 2Not Yet Recruiting

A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors

NCT03628521Phase 1Unknown

First-line Combination Treatment Based on Anlotinib

Showing all 2 trials

Research Network

Activity Timeline